Evaluation of Prophylactic EGD versus Beta Blockade in Hepatocellular Carcinoma Patients on Anti-Angiogenic Cancer Treatments
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Panayiotis D Kontoyiannis,1 Camila Ayerbe,2 Kok Hoe Chan,3 Sara Soliman,4 Victor Machicao,5 Julie H Rowe4 1Department of Internal Medicine, The University of Southwestern Medical Center, Dallas, TX, USA; 2Department of Internal Medicine and Pediatrics, The University of Southwestern Medical Center, Dallas, TX, USA; 3Department of Medicine, CAMC Institute for Academic Medicine, Charleston Area Medical Center, Charleston, WV, USA; 4Department of Internal Medicine, Division of Oncology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA; 5Department of Internal Medicine, Division of Hepatology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USACorrespondence: Julie H Rowe, Department of Internal Medicine, Division of Oncology, The University of Texas Health Science Center at Houston, 6410 Fannin St., Ste. 830, Houston, TX, 77030, USA, Email Julie.Rowe@uth.tmc.edu
Fields of Study & Subjects
Hepatocellular Carcinoma Treatment and Prognosis
Gastrointestinal Bleeding Diagnosis and Treatment
Gastric Cancer Management and Outcomes
Publication details
- Journal / source
- Journal of Hepatocellular Carcinoma
- Volume
- Volume 13
- Pages
- 1–10
- Publication date
- 1 March 2026
- Language
- EN